SS Innovations (SSII) Stock News

SS Innovations (Nasdaq: SSII) announced regulatory approval for telesurgeries using its SSi Mantra surgical robotic system in Indonesia and the Philippines on March 18, 2026. The company also reported surpassing 150 cumulative telesurgeries, with high‑volume sessions in India demonstrating multi‑case capability.

Recent operational highlights include 18 inter‑hospital telesurgeries on February 14, 2026, and a 24‑case telesurgery marathon on December 23, 2025, using the portable SSi MantraAsana console.

SS Innovations (Nasdaq: SSII) reported strong 2025 growth with revenue up 105.7% to $42.5M and gross margin expanding to 46.0%. SSi Mantra installations rose to 103 (+119.1%) and cumulative surgeries reached 7,885. The company completed a private placement raising ~$18.6M and had $3.2M cash as of December 31, 2025.

Fourth-quarter revenue was $14.5M (+79.1%) with 40 installations. Full-year net loss improved to $12.1M from $19.2M in 2024. Management expects FDA 510(k) review by mid-2026 and continued global expansion.

SS Innovations (NASDAQ: SSII) completed a private placement on March 6, 2026, raising approximately $18.6 million in gross proceeds through the sale of 5,774,839 common shares.

The offering included insider purchases by the CEO, vice-chairman and a director, a $2.5 million investor that triggered a 7% cash commission and five-year warrants, and participation led by Manipal Global Health Services. Proceeds will fund working capital and global expansion, including planned U.S. FDA 510(k) review and EU CE marking efforts for the SSi Mantra surgical robotic system.

SS Innovations (Nasdaq: SSII) reported preliminary unaudited results for Q4 and full-year 2025 showing significant unit and revenue growth. Q4 2025 revenue is estimated at $15.0 million, up 85% from $8.1 million a year earlier, with 37 SSi Mantra installations in the quarter, up 68% year-over-year. Full-year 2025 revenue is estimated at $43.0 million, up 108% from $20.6 million in 2024, and 103 SSi Mantra installations for the year, up 119%.

The cumulative installed base reached 168 systems at year-end 2025. Management said FDA 510(k) review and EU CE marking are anticipated in the first half of 2026. Results are preliminary, unaudited and subject to final quarter-end procedures and change.

SS Innovations (Nasdaq: SSII) appointed Milan Rao as Global Chief Operating Officer and Chief Financial Officer effective January 8, 2026. The Global COO role is newly created; Mr. Rao will succeed Naveen Kumar Amar as CFO following Mr. Amar’s resignation for personal reasons and will be based in the United States during a planned transition period. Mr. Rao brings more than three decades of leadership across healthcare, technology and financial services, with prior roles at Markets and Markets, Wipro, GE Healthcare, Morgan Stanley and Citibank.

The company said Mr. Rao will support growth strategy, operational readiness and scaling of the SSi Mantra surgical robotic platform.

SS Innovations (Nasdaq: SSII) announced completion of five new 5-millimeter surgical instruments for clinical use with its SSi Mantra robotic system, targeting pediatric, cardiac, and head-and-neck procedures. The instruments are a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps.

As of Dec 31, 2025, the SSi Mantra installed base totaled 168 systems across 153 hospitals, with more than 7,800 procedures performed, including over 120 telesurgeries and more than 400 cardiac procedures. The company says the smaller instruments aim to expand robotic access for children and other patients with small anatomical structures.

SS Innovations (Nasdaq: SSII) submitted a 510(k) premarket notification to the FDA on Dec 5, 2025 for the SSi Mantra surgical robotic system covering general, urological, colorectal, gynecological and cardiac surgeries.

The company said it chose the 510(k) pathway following FDA pre-submission talks to seek faster, lower-cost review; the FDA aims for 90-day reviews but noted potential delays from the 15-day acceptance review or requests for more information. SS Innovations also expects possible EU CE marking in H1 2026.

As of Nov 30, 2025, the SSi Mantra installed base totaled 138 systems across eight countries, with 137 hospitals and over 7,300 procedures performed, including 88 telesurgeries and 390 cardiac procedures.

SS Innovations (Nasdaq: SSII) announced completion of its first telesurgery using the new SSi Mantra Tele Surgeon Console (TSC). On October 17, 2025, Dr. Sudhir Srivastava remotely performed a robotic-assisted coronary artery bypass from his residence in New Delhi on a patient about 185 miles away at Manipal Hospital in Jaipur.

The TSC is a compact, chair-based version of the SSi Mantra surgeon command center, designed for portability and smaller footprint so consoles can be placed in physician offices rather than full operating rooms. The device features lightweight glasses with magnified 3D view, magnetic sensor controls, and follows refinements made since its June 2024 showcase.

SS Innovations (Nasdaq: SSII) reported third quarter 2025 results on October 28, 2025. Q3 revenue rose 192.5% to $12.8M from $4.4M, driven by higher SSi Mantra 3 unit sales; gross profit increased 166.0% to $6.2M while gross margin narrowed to 48.1% from 52.8% a year earlier. The company reported a Q3 net loss of $3.7M (‑$0.02 per diluted share). Installations totaled 27 in Q3 (cumulative 127 across seven countries) and cumulative surgeries reached 6,057. Year-to-date revenue rose 123.0% to $28.0M. As of September 30, 2025, cash and cash equivalents were $5.7M and long-term debt was $0. Management expects to submit a 510(k) to FDA in Q4 2025 and pursue EU CE marking in H1 2026.